Design, Synthesis, and In vitro Antitumor Evaluation of Novel Phenylaminopyrimidine Derivatives

被引:1
作者
Zheng, Youguang [1 ,2 ]
Zheng, Ming [2 ]
Liu, Yi [1 ]
Xue, Yunsheng [1 ]
Zhang, Ling [1 ]
An, Lin [1 ]
Liu, Ling [1 ]
Ji, Min [2 ]
机构
[1] Xuzhou Med Coll, Coll Pharm, Xuzhou 221004, Peoples R China
[2] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Jiangsu, Peoples R China
关键词
Phenylaminopyrimidine derivatives; U937; K562; antitumor activity; AURORA KINASE INHIBITORS; POTENT; DISCOVERY; VX-680; CANCER;
D O I
10.2174/1573406411309030004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two series of novel phenylaminopyrimidine derivatives were designed and synthesized. All target compounds were determined against the human acute monocytic leukemia cell line U937 and the human chronic myeloid leukemia cell line K562 in vitro. Some of the target compounds demonstrated significant inhibitory activity against both cell lines. Compared with the control drug VX-680, 8a, 8e, 8g, 8h, 8j, and 8k demonstrated more potent antitumor activity. The structures of all target compounds were identified by H-1-NMR, C-13-NMR, IR, MS, and EA.
引用
收藏
页码:340 / 350
页数:11
相关论文
共 17 条
[1]   Aurora kinases: shining lights on the therapeutic horizon? [J].
Andrews, PD .
ONCOGENE, 2005, 24 (32) :5005-5015
[2]   The discovery of the potent aurora inhibitor MK-0457 (VX-680) [J].
Bebbington, David ;
Binch, Hayley ;
Charrier, Jean-Damien ;
Everitt, Simon ;
Fraysse, Damien ;
Golec, Julian ;
Kay, David ;
Knegtel, Ronald ;
Mak, Chau ;
Mazzei, Francesca ;
Miller, Andrew ;
Mortimore, Michael ;
O'Donnell, Michael ;
Patel, Sanjay ;
Pierard, Francoise ;
Pinder, Joanne ;
Pollard, John ;
Ramaya, Sharn ;
Robinson, Daniel ;
Rutherford, Alistair ;
Studley, John ;
Westcott, James .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (13) :3586-3592
[3]  
Bray M. R., 2008, P 99 AACR ANN M
[4]   Aurora kinase inhibitors: identification and preclinical validation of their biomarkers [J].
Carpinelli, Patrizia ;
Moll, Juergen .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (01) :69-80
[5]  
Charrier J. D., 2004, U.S. Patent, Patent No. [2,004,049,032, 2004049032]
[6]   A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models [J].
Emanuel, S ;
Gruninger, RH ;
Fuentes-Pesquera, A ;
Connolly, PJ ;
Seamon, JA ;
Hazel, S ;
Tominovich, R ;
Hollister, B ;
Napier, C ;
D'Andrea, MR ;
Reuman, M ;
Bignan, G ;
Tuman, R ;
Johnson, D ;
Moffatt, D ;
Batchelor, M ;
Foley, A ;
O'Connell, J ;
Allen, R ;
Perry, M ;
Jolliffe, L ;
Middleton, SA .
MOLECULAR PHARMACOLOGY, 2004, 66 (03) :635-647
[7]   Aurora kinase inhibitors: A new class of targeted drugs in cancer [J].
Gautschi, Oliver ;
Mack, Philip C. ;
Davies, Angela M. ;
Lara, Primo N., Jr. ;
Gandara, David R. .
CLINICAL LUNG CANCER, 2006, 8 (02) :93-98
[8]  
Griffiths G., 2008, P 99 AACR ANN M
[9]   VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo [J].
Harrington, EA ;
Bebbington, D ;
Moore, J ;
Rasmussen, RK ;
Ajose-Adeogun, AO ;
Nakayama, T ;
Graham, JA ;
Demur, C ;
Hercend, T ;
Diu-Hercend, A ;
Su, M ;
Golec, JMC ;
Miller, KM .
NATURE MEDICINE, 2004, 10 (03) :262-267
[10]   Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity [J].
Howard, Steven ;
Berdini, Valerio ;
Boulstridge, John A. ;
Carr, Maria G. ;
Cross, David M. ;
Curry, Jayne ;
Devine, Lindsay A. ;
Early, Theresa R. ;
Fazal, Lynsey ;
Gill, Adrian L. ;
Heathcote, Michelle ;
Maman, Sarita ;
Matthews, Julia E. ;
McMenamin, Rachel L. ;
Navarro, Eva F. ;
O'Brien, Michael A. ;
O'Reilly, Marc ;
Rees, David C. ;
Reule, Matthias ;
Tisi, Dominic ;
Williams, Glyn ;
Vinkovic, Mladen ;
Wyatt, Paul G. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (02) :379-388